Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-6-Avelumab
2018-002010-12Phase 2Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jan 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab, cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Progression-free survival. Started Jan 2019; status: completed.
02
Drugs
avelumabcetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-002010-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002010-12.